利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1163 条记录 (耗时 0.05 秒)

    FREE NGAL AS A BIOMARKER FOR CANCER
    2.
    发明申请
    FREE NGAL AS A BIOMARKER FOR CANCER 审中-公开

    公开(公告)号：US20180238896A1

    公开(公告)日：2018-08-23

    申请号：US15712692

    申请日：2017-09-22

    申请人： Children's Medical Center Corporation

    发明人： Marsha A. Moses ,  Jiang Yang

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57496 ,  G01N33/57415 ,  G01N33/57449 ,  G01N33/57488 ,  G01N2333/47

    摘要： Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer.

    Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles
    9.
    发明授权
    Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles 有权

    公开(公告)号：US09970938B2

    公开(公告)日：2018-05-15

    申请号：US15060998

    申请日：2016-03-04

    申请人： Basilea Pharmaceutica AG

    发明人： Heidi Alexandra Lane ,  Felix Bachmann ,  Madlaina Breuleux ,  Michael Boutros ,  Daniel Gilbert ,  Xian Zhang

    IPC分类号： G01N33/574 ,  A61K31/4245 ,  G01N33/50 ,  A61K31/4439 ,  C12Q1/68

    CPC分类号： G01N33/57484 ,  A61K31/4245 ,  A61K31/4439 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/5026 ,  G01N33/57496 ,  G01N2333/91205 ,  G01N2800/44 ,  G01N2800/52

    摘要： Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a compound of general formula I wherein R represents phenyl, thienyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; X represents a group C═Y, wherein Y stands for oxygen or nitrogen substituted by hydroxy or lower alkoxy; R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; R2, R3 and R6 represent hydrogen; R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; or R4 and R5 together represent methylenedioxy; and pharmaceutically acceptable derivatives thereof; or wherein R represents phenyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; X represents oxygen; R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; R2, R3 and R6 represent hydrogen; R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; or R4 and R5 together represent methylenedioxy; and pharmaceutically acceptable derivatives thereof. Methods of treatment of neoplastic and autoimmune diseases with these compounds are also disclosed.